Payment overview · 2025
General Payments
$851.18
40 reported records · 15 companies
Healthcare provider profile · identity verified
Nidal Shawahin, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BELLEVILLE, IL · NPI 1245236884
Verified facts
What the public records show
CMS Open Payments records show Nidal Shawahin, MD received $851.18 in general payments during 2025 across 40 reported records.
AstraZeneca Pharmaceuticals LP accounted for 33.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 242 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Symbicort by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 271 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $283.64 | 33.3% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $110.25 | 12.9% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $97.96 | 11.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.79 | 6.2% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $47.12 | 5.5% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $41.93 | 4.9% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.54 | 4.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.04 | 4.1% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $24.82 | 2.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.28 | 2.9% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $23.17 | 2.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.34 | 2.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.81 | 2.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.99 | 1.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.50 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $812.64 | 39 |
| Education | $38.54 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $202.61 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $123.53 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $100.36 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $83.96 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $60.46 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $47.12 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $42.06 | 2 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $41.93 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $38.54 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $37.50 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $37.50 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $35.04 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.74 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $26.29 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 242 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 212 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 80 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 194 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 271 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
80 | 30 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
82 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
242 | 54 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
128 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
212 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
194 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
271 | 51 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
222 | 53 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1111 | 283 |
| Amlodipine Besylate | Amlodipine Besylate | 1044 | 293 |
| Atorvastatin Calcium | Atorvastatin Calcium | 866 | 244 |
| Metoprolol Succinate | Metoprolol Succinate | 586 | 171 |
| Omeprazole | Omeprazole | 527 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 518 | 138 |
| Lisinopril | Lisinopril | 483 | 133 |
| Furosemide | Furosemide | 479 | 154 |
| Metformin Hcl | Metformin Hcl | 455 | 123 |
| Tramadol Hcl | Tramadol Hcl | 455 | 97 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 406 | 128 |
| Gabapentin | Gabapentin | 390 | 105 |
| Losartan Potassium | Losartan Potassium | 379 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 371 | 105 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 348 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 304 | 87 |
| Zolpidem Tartrate | Zolpidem Tartrate | 304 | 42 |
| Trazodone Hcl | Trazodone Hcl | 299 | 59 |
| Potassium Chloride | Potassium Chloride | 284 | 74 |
| Ozempic | Semaglutide | 271 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 269 | 80 |
| Simvastatin | Simvastatin | 261 | 75 |
| Farxiga | Dapagliflozin Propanediol | 242 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 234 | 76 |
| Eliquis | Apixaban | 222 | 53 |
| Jardiance | Empagliflozin | 212 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 210 | 63 |
| Allopurinol | Allopurinol | 204 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 200 | 59 |
| Glimepiride | Glimepiride | 197 | 62 |
| Ezetimibe | Ezetimibe | 196 | 59 |
| Mounjaro | Tirzepatide | 194 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 189 | 49 |
| Alprazolam | Alprazolam | 188 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 181 | 48 |
| Donepezil Hcl | Donepezil Hcl | 179 | 31 |
| Irbesartan | Irbesartan | 170 | 41 |
| Lorazepam | Lorazepam | 165 | 29 |
| Famotidine | Famotidine | 162 | 38 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 160 | 30 |
| Carvedilol | Carvedilol | 159 | 46 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 152 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 151 | 81 |
| Pregabalin | Pregabalin | 150 | 29 |
| Alendronate Sodium | Alendronate Sodium | 146 | 47 |
| Sertraline Hcl | Sertraline Hcl | 143 | 42 |
| Valsartan | Valsartan | 134 | 40 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 132 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 130 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 129 | 35 |
| Xarelto | Rivaroxaban | 128 | 29 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 122 | 30 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 116 | 32 |
| Meloxicam | Meloxicam | 113 | 34 |
| Doxazosin Mesylate | Doxazosin Mesylate | 107 | 31 |
| Spironolactone | Spironolactone | 105 | 32 |
| Montelukast Sodium | Montelukast Sodium | 103 | 34 |
| Ropinirole Hcl | Ropinirole Hcl | 100 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 98 | 28 |
| Memantine Hcl | Memantine Hcl | 97 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 27 |
| Sildenafil Citrate | Sildenafil Citrate | 95 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 94 | 28 |
| Atenolol | Atenolol | 91 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 24 |
| Myrbetriq | Mirabegron | 90 | 19 |
| Celecoxib | Celecoxib | 86 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 83 | 22 |
| Mirtazapine | Mirtazapine | 82 | 28 |
| Synthroid | Levothyroxine Sodium | 82 | 17 |
| Baclofen | Baclofen | 81 | 37 |
| Linzess | Linaclotide | 80 | 30 |
| Finasteride | Finasteride | 78 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 19 |
| Metformin Hcl Er | Metformin Hcl | 74 | 23 |
| Warfarin Sodium | Warfarin Sodium | 73 | 13 |
| Clonidine Hcl | Clonidine Hcl | 72 | 21 |
| Tresiba Flextouch U-200 | Insulin Degludec | 71 | 18 |
| Entresto | Sacubitril/Valsartan | 68 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 68 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 66 | 50 |
| Azithromycin | Azithromycin | 65 | 55 |
| Fenofibrate | Fenofibrate | 65 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 19 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 16 |
| Ibuprofen | Ibuprofen | 62 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 41 |
| Fenofibrate | Fenofibrate Nanocrystallized | 61 | 19 |
| Trulicity | Dulaglutide | 61 | 15 |
| Glipizide | Glipizide | 60 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 12 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 60 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 20 |
| Clonazepam | Clonazepam | 57 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 57 | 29 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 56 | 20 |
| Telmisartan | Telmisartan | 54 | 13 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 52 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 52 | 16 |
| Januvia | Sitagliptin Phosphate | 50 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 50 | 14 |
| Meclizine Hcl | Meclizine Hcl | 49 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 12 |
| Prednisone | Prednisone | 49 | 24 |
| Levetiracetam | Levetiracetam | 48 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 48 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 31 |
| Hydrocortisone | Hydrocortisone | 45 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 45 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 45 | suppressed |
| Ondansetron Odt | Ondansetron | 44 | 22 |
| Bupropion Xl | Bupropion Hcl | 43 | 12 |
| Diazepam | Diazepam | 43 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 13 |
| Repatha Sureclick | Evolocumab | 41 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 14 |
| Rybelsus | Semaglutide | 40 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 39 | 37 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 39 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 37 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 37 | suppressed |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 29 |
| Nortriptyline Hcl | Nortriptyline Hcl | 36 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Fluconazole | Fluconazole | 35 | 28 |
| Klor-Con M20 | Potassium Chloride | 35 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 11 |
| Doxepin Hcl | Doxepin Hcl | 34 | suppressed |
| Folic Acid | Folic Acid | 34 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Bumetanide | Bumetanide | 32 | 12 |
| Eszopiclone | Eszopiclone | 31 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 30 | 11 |
| Naproxen | Naproxen | 30 | 17 |
| Primidone | Primidone | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 24 |
| Trueplus Pen Needle | Pen Needle, Diabetic | 29 | 12 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 13 |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Fentanyl | Fentanyl | 26 | suppressed |
| Gemtesa | Vibegron | 26 | suppressed |
| Nystatin | Nystatin | 26 | 18 |
| Trospium Chloride Er | Trospium Chloride | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Repatha Syringe | Evolocumab | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Cefdinir | Cefdinir | 19 | 17 |
| Dilt-Xr | Diltiazem Hcl | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 15 |
| Sucralfate | Sucralfate | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Benzonatate | Benzonatate | 18 | 14 |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 17 | 16 |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Oxycontin | Oxycodone Hcl | 16 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 16 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | 12 |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Estradiol | Estradiol | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $851.18 · 40 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AJOVY, Auvelity, BREZTRI, CREON, EVENITY, FARXIGA, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, Omnipod, Ozempic, QULIPTA, REXULTI, Rybelsus, SPRAVATO, TRINTELLIX, The Cologuard Plus Collection Kit, VERQUVO, Wegovy, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error